Skip to main content
SpringerLink
Log in

Novel Therapies on the Horizon

  • Chapter
Malignant Pediatric Bone Tumors - Treatment & Management

Part of the book series: Pediatric Oncology ((PEDIATRICO))

  • 1083 Accesses

Abstract

As many of the prior chapters illustrate, we have had many successes in the treatment of children with malignant bone tumors. Nevertheless, there is a substantial fraction of patients who are not cured by current therapies. In addition, even those who are long term survivors often suffer chronic side effects of treatment. Thus, we need to continue to explore novel therapies both to increase the cure rates and decrease complications. In this chapter we review available data for a variety of new therapies including novel small molecules, immunotherapies, and virotherapy, with an emphasis on findings in preclinical models or early phase clinical trials in patients with bone cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Akers SN, Odunsi K, Karpf AR (2010) Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol 6:717–732

    CAS  PubMed Central  PubMed  Google Scholar 

  • Akiyama T, Dass CR, Shinoda Y, Kawano H, Tanaka S, Choong PF (2010) Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts. J Pharm Pharmacol 62:470–476

    CAS  PubMed  Google Scholar 

  • Bachner D, Schroder D, Gross G (2002) mRNA expression of the murine glycoprotein (transmembrane) nmb (Gpnmb) gene is linked to the developing retinal pigment epithelium and iris. Brain Res Gene Expr Patterns 1:159–165

    CAS  PubMed  Google Scholar 

  • Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S (2014) Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children’s Oncology Group Study. Pediatr Blood Cancer 61:833–839

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bago-Horvath Z, Schmid K, Rossler F, Nagy-Bojarszky K, Funovics P, Sulzbacher I (2014) Impact of RANK signalling on survival and chemotherapy response in osteosarcoma. Pathology 46:411–415

    CAS  PubMed  Google Scholar 

  • Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E (1991) Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 266:15882–15889

    CAS  PubMed  Google Scholar 

  • Barber-Rotenberg JS, Selvanathan SP, Kong Y, Erkizan HV, Snyder TM, Hong SP, Kobs CL, South NL, Summer S, Monroe PJ et al (2012) Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget 3:172–182

    PubMed Central  PubMed  Google Scholar 

  • Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM, Gottardis MM, Haluska P (2012) IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res Off J Am Assoc Cancer Res 18:1808–1817

    CAS  Google Scholar 

  • Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, Nuyens JP, Earl N, St-Jean M, Holbrook J et al (2014) Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol 32:182–190

    CAS  PubMed  Google Scholar 

  • Bharatan NS, Currier MA, Cripe TP (2002) Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J Pediatr Hematol Oncol 24:447–453

    PubMed  Google Scholar 

  • Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ (2012) Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol Cancer Ther 11:649–659

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ (2013) Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy. Clin Cancer Res Off J Am Assoc Cancer Res 19:2984–2994

    CAS  Google Scholar 

  • Bid HK, Roberts RD, Cam M, Audino A, Kurmasheva RT, Lin J, Houghton PJ, Cam H (2014) DeltaNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis. Cancer Res 74:320–329

    CAS  PubMed Central  PubMed  Google Scholar 

  • Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335–348

    CAS  PubMed  Google Scholar 

  • Bostedt KT, Schmid C, Ghirlanda-Keller C, Olie R, Winterhalter KH, Zapf J (2001) Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells. Exp Cell Res 271:368–377

    CAS  PubMed  Google Scholar 

  • Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M, Armatis P (2002) Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer 95:1735–1745

    CAS  PubMed  Google Scholar 

  • Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J et al (2011) Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19:664–678

    CAS  PubMed Central  PubMed  Google Scholar 

  • Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA, Chinnaiyan AM (2012) PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res 72:1608–1613

    CAS  PubMed Central  PubMed  Google Scholar 

  • Buddingh EP, Schilham MW, Ruslan SE, Berghuis D, Szuhai K, Suurmond J, Taminiau AH, Gelderblom H, Egeler RM, Serra M et al (2011) Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 60:575–586

    CAS  PubMed Central  PubMed  Google Scholar 

  • Burke JM, Ahern C, Weigel B, Poirier J, Rudin C, Chen Y, Cripe TP, Bernhardt M, Blaney SM (2015) Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children’s Oncology Group. Pediatr Blood Cancer 62:743–750

    CAS  PubMed  Google Scholar 

  • Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154–169

    CAS  PubMed  Google Scholar 

  • Casanova M, Ferrari A, Spreafico F, Terenziani M, Massimino M, Luksch R, Cefalo G, Polastri D, Marcon I, Bellani FF (2002) Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 94:3263–3268

    CAS  PubMed  Google Scholar 

  • Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D’Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L et al (2012) Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol Off J Am Soc Clin Oncol 30:78–84

    CAS  Google Scholar 

  • Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D (2010) Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16:3901–3909

    CAS  PubMed Central  PubMed  Google Scholar 

  • Choy E, Butrynski JE, Harmon D et al (2013) Translation of preclinical predictive sensitivity of Ewing sarcoma to PARP inhibition: phase II study of olaparib in adult patients with recurrent/metastatic Ewing sarcoma following failure of prior chemotherapy. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research Abstr #LB-174

    Google Scholar 

  • Chung JS, Dougherty I, Cruz PD Jr, Ariizumi K (2007a) Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J Immunol 179:5778–5784

    CAS  PubMed  Google Scholar 

  • Chung JS, Sato K, Dougherty II, Cruz PD Jr, Ariizumi K (2007b) DC-HIL is a negative regulator of T lymphocyte activation. Blood 109:4320–4327

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063–2073

    CAS  PubMed  Google Scholar 

  • Coley WB (1933) The treatment of sarcoma of the long bones. Ann Surg 97:434–460

    CAS  PubMed Central  PubMed  Google Scholar 

  • Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney DM, Pelusio A, Moon A et al (2015) Phase I study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther 23:602–608

    CAS  PubMed  Google Scholar 

  • Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH et al (2013) VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Mol Ther 21:1014–1023

    CAS  PubMed Central  PubMed  Google Scholar 

  • Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2:740–749

    CAS  PubMed  Google Scholar 

  • de Alava E, Panizo A, Antonescu CR, Huvos AG, Pardo-Mindan FJ, Barr FG, Ladanyi M (2000) Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing’s sarcoma. Am J Pathol 156:849–855

    PubMed Central  PubMed  Google Scholar 

  • De Bono JS, Mina LA, Gonzalez M, Curtin NJ, Wang E, Henshaw JW, Chadha M, Sachdev JC, Matei D, Jameson GS et al (2013) First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J Clin Oncol 31 (Suppl):abstr 2580

    Google Scholar 

  • Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G et al (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162–165

    CAS  PubMed  Google Scholar 

  • Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O (2009) Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 15:5445–5456

    CAS  PubMed  Google Scholar 

  • Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ (1994) Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 54:903–907

    CAS  PubMed  Google Scholar 

  • Dobrynin P, Matyunina E, Malov SV, Kozlov AP (2013) The novelty of human cancer/testis antigen encoding genes in evolution. Int J Genom 2013:105108

    Google Scholar 

  • DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, Marina N, Grier HE, Stegmaier K, and Children’s Oncology (2009) Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 52:324–327

    Google Scholar 

  • Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP et al (2012) Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children’s Oncology Group. J Clin Oncol 30:2545–2551

    CAS  PubMed Central  PubMed  Google Scholar 

  • Edmonson JH, Green SJ, Ivins JC, Gilchrist GS, Creagan ET, Pritchard DJ, Smithson WA, Dahlin DC, Taylor WF (1984) A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 2:152–156

    CAS  PubMed  Google Scholar 

  • Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J (1987) Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5:21–26

    CAS  PubMed  Google Scholar 

  • Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML et al (2009) A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nat Med 15:750–756

    CAS  PubMed Central  PubMed  Google Scholar 

  • Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN (2002) Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62:7291–7297

    CAS  PubMed  Google Scholar 

  • Ferrari S, Palmerini E (2007) Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19:341–346

    CAS  PubMed  Google Scholar 

  • Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C et al (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512–2519

    CAS  PubMed  Google Scholar 

  • Fouladi M, Laningham F, Wu J, O’Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ et al (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 25:4806–4812

    CAS  Google Scholar 

  • Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY (2009) Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther 17:1125–1135

    CAS  PubMed Central  PubMed  Google Scholar 

  • Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF (2006) Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther 5:1079–1086

    CAS  PubMed  Google Scholar 

  • Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM et al (2012) Phase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 20:1998–2003

    CAS  PubMed Central  PubMed  Google Scholar 

  • Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J et al (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570–575

    CAS  PubMed Central  PubMed  Google Scholar 

  • Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE et al (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res Off J Am Assoc Cancer Res 15:4207–4212

    CAS  Google Scholar 

  • Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, Corvaia N (2005) A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113:316–328

    CAS  PubMed  Google Scholar 

  • Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM et al (2010) Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 28:641–649

    PubMed  Google Scholar 

  • Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH et al (2012) Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 59:518–524

    PubMed Central  PubMed  Google Scholar 

  • Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J et al (2011) Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 103:962–978

    CAS  PubMed Central  PubMed  Google Scholar 

  • Guerreiro AS, Boller D, Doepfner KT, Arcaro A (2006) IGF-IR: potential role in antitumor agents. Drug News Perspect 19:261–272

    CAS  PubMed  Google Scholar 

  • Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2:pe24

    PubMed  Google Scholar 

  • Guse K, Cerullo V, Hemminki A (2011) Oncolytic vaccinia virus for the treatment of cancer. Expert Opin Biol Ther 11:595–608

    CAS  PubMed  Google Scholar 

  • Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM et al (2006) In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 66:362–371

    CAS  PubMed  Google Scholar 

  • Hammill AM, Conner J, Cripe TP (2010) Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer 55:1253–1263

    PubMed  Google Scholar 

  • Han EQ, Li XL, Wang CR, Li TF, Han SY (2013) Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol 6:47

    CAS  PubMed Central  PubMed  Google Scholar 

  • Himoudi N, Wallace R, Parsley KL, Gilmour K, Barrie AU, Howe K, Dong R, Sebire NJ, Michalski A, Thrasher AJ, Anderson J (2012) Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin Transl Oncol 14:271–279

    CAS  PubMed  Google Scholar 

  • Hingorani P, Zhang W, Lin J, Liu L, Guha C, Kolb EA (2011) Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. Cancer 117:1764–1774

    CAS  PubMed  Google Scholar 

  • Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A et al (2008) Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A 105:20422–20427

    CAS  PubMed Central  PubMed  Google Scholar 

  • Hong SH, Youbi SE, Hong SP, Kallakury B, Monroe P, Erkizan HV, Barber-Rotenberg JS, Houghton P, Uren A, Toretsky JA (2014) Pharmacokinetic modeling optimizes inhibition of the ‘undruggable’ EWS-FLI1 transcription factor in Ewing Sarcoma. Oncotarget 5:338–350

    PubMed Central  PubMed  Google Scholar 

  • Horton JK, Wilson SH (2013) Predicting enhanced cell killing through PARP inhibition. Mol Cancer Res 11:13–18

    CAS  PubMed Central  PubMed  Google Scholar 

  • Houchens DP, Ovejera AA, Riblet SM, Slagel DE (1983) Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 19:799–805

    CAS  PubMed  Google Scholar 

  • Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50:799–805

    PubMed  Google Scholar 

  • Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA et al (2010a) Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 9:101–112

    CAS  PubMed Central  PubMed  Google Scholar 

  • Houghton PJ, Morton CL, Kang M, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA (2010b) Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr Blood Cancer 55:1224–1226

    PubMed  Google Scholar 

  • Hromas R, Klemsz M (1994) The ETS oncogene family in development, proliferation and neoplasia. Int J Hematol 59:257–265

    CAS  PubMed  Google Scholar 

  • Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A et al (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69:161–170

    CAS  PubMed  Google Scholar 

  • Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, Fargnoli J, Graf Finckenstein F, Gottardis MM, Carboni JM (2010) Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 70:7221–7231

    CAS  PubMed  Google Scholar 

  • Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281

    CAS  PubMed  Google Scholar 

  • Jackson-Booth PG, Terry C, Lackey B, Lopaczynska M, Nissley P (2003) Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation. Horm Metab Res 35:850–856

    CAS  PubMed  Google Scholar 

  • Jain S, Vahdat LT (2011) Eribulin mesylate. Clin Cancer Res Off J Am Assoc Cancer Res 17:6615–6622

    CAS  Google Scholar 

  • Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265

    CAS  PubMed  Google Scholar 

  • Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086–1095

    CAS  PubMed  Google Scholar 

  • Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, Titze U, Leuchte K, Landmeier S, Hotfilder M et al (2012) The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer 106:1123–1133

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kakarla S, Chow K, Mata M, Shaffer DR, Song XT, Wu MF, Liu H, Wang LL, Rowley DR, Pfizenmaier K, Gottschalk S (2013) Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 21:1611–1620

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kalebic T, Tsokos M, Helman LJ (1994) In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 54:5531–5534

    CAS  PubMed  Google Scholar 

  • Kang Z, Yu Y, Zhu YJ, Davis S, Walker R, Meltzer PS, Helman LJ, Cao L (2013) Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma. Oncogene 33:5697

    PubMed  Google Scholar 

  • Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D et al (2014) Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer 61:1486–1489

    CAS  PubMed  Google Scholar 

  • Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17:718–730

    PubMed  Google Scholar 

  • Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, Mitchell G, Fried G, Bowen K, Fielding A, Domchek SM (2013) Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: an open-label phase II study. J Clin Oncol 31 (Suppl):abstr 11024

    Google Scholar 

  • Kedar PS, Stefanick DF, Horton JK, Wilson SH (2012) Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. Mol Cancer Res 10:360–368

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kelly E, Russell SJ (2007) History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15:651–659

    CAS  PubMed  Google Scholar 

  • Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S (2012) Immunotherapy of cancer in 2012. CA Cancer J Clin 62:309–335

    PubMed Central  PubMed  Google Scholar 

  • Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM et al (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709–2720

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kofman S, Perlia CP, Economou SG (1973) Mithramycin in the treatment of metastatic Ewing’s sarcoma. Cancer 31:889–893

    CAS  PubMed  Google Scholar 

  • Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P, Gorlick R (2010) R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 55:67–75

    PubMed  Google Scholar 

  • Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C et al (2011) Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 56:595–603

    PubMed Central  PubMed  Google Scholar 

  • Kolb EA, Gorlick R, Maris JM, Keir ST, Morton CL, Wu J, Wozniak AW, Smith MA, Houghton PJ (2012) Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 58:729–735

    PubMed Central  PubMed  Google Scholar 

  • Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C et al (2013) Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 60:1325–1332

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kolb EA, Sampson V, Stabley D, Walter A, Sol-Church K, Cripe TP, Hingorani P, Ahem C, Weigel B, Zwiebel J, Blaney SM (2015) A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children’s Oncology Group phase I consortium report. Pediatr Blood Cancer 62:751–758

    CAS  PubMed  Google Scholar 

  • Krailo M, Ertel I, Makley J, Fryer CJ, Baum E, Weetman R, Yunis E, Barnes L, Bleyer WA, Hammond GD (1987) A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group. Med Pediatr Oncol 15:69–77

    CAS  PubMed  Google Scholar 

  • Kuan CT, Wakiya K, Dowell JM, Herndon JE 2nd, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD (2006) Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 12:1970–1982

    CAS  PubMed  Google Scholar 

  • Kurmasheva RT, Houghton PJ (2006) IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766:1–22

    CAS  PubMed  Google Scholar 

  • Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ (2009) The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 69:7662–7671

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lechner MG, Russell SM, Bass RS, Epstein AL (2011) Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy 3:1317–1340

    CAS  PubMed Central  PubMed  Google Scholar 

  • Lee S, Margolin K (2011) Cytokines in cancer immunotherapy. Cancers (Basel) 3:3856–3893

    CAS  Google Scholar 

  • Lee HJ, Yoon C, Schmidt B, Park do J, Zhang AY, Erkizan HV, Toretsky JA, Kirsch DG, Yoon SS (2013) Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Mol Cancer Ther 12:2591–2600

    CAS  PubMed  Google Scholar 

  • Li Z (2013) Potential of human gammadelta T cells for immunotherapy of osteosarcoma. Mol Biol Rep 40:427–437

    PubMed  Google Scholar 

  • Lipinski M, Braham K, Philip I, Wiels J, Philip T, Dellagi K, Goridis C, Lenoir GM, Tursz T (1986) Phenotypic characterization of Ewing sarcoma cell lines with monoclonal antibodies. J Cell Biochem 31:289–296

    CAS  PubMed  Google Scholar 

  • Liu WN, Lin JH, Cheng YR, Zhang L, Huang J, Wu ZY, Wang FS, Xu SG, Lin WP, Lan WB, Yang GX (2013) FIM-A, a phosphorus-containing sirolimus, inhibits the angiogenesis and proliferation of osteosarcomas. Oncol Res 20:319–326

    CAS  PubMed  Google Scholar 

  • Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA et al (2012) Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer 58:916–923

    PubMed Central  PubMed  Google Scholar 

  • Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E et al (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118:6050–6056

    CAS  PubMed Central  PubMed  Google Scholar 

  • MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, Wilson M, Radinsky R (2004) IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92:77–91

    CAS  PubMed  Google Scholar 

  • Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M et al (2008) A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 14:4850–4858

    CAS  PubMed Central  PubMed  Google Scholar 

  • Marr LA, Gilham DE, Campbell JD, Fraser AR (2012) Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. Clin Exp Immunol 167:216–225

    CAS  PubMed Central  PubMed  Google Scholar 

  • Masutani M, Nozaki T, Nakamoto K, Nakagama H, Suzuki H, Kusuoka O, Tsutsumi M, Sugimura T (2000) The response of Parp knockout mice against DNA damaging agents. Mutat Res 462:159–166

    CAS  PubMed  Google Scholar 

  • Meyers PA, Chou AJ (2014) Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. Adv Exp Med Biol 804:307–321

    CAS  PubMed  Google Scholar 

  • Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–2011

    CAS  PubMed  Google Scholar 

  • Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA et al (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5:221–230

    CAS  PubMed  Google Scholar 

  • Morgenstern DA, Marzouki M, Bartels U, Irwin MS, Sholler GL, Gammon J, Yankanah R, Wu B, Samson Y, Baruchel S (2014) Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. Pediatr Blood Cancer 61:128–133

    CAS  PubMed  Google Scholar 

  • Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG et al (2010) Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res 70:10329–10339

    CAS  PubMed Central  PubMed  Google Scholar 

  • Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA (2010) Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer 55:295–303

    PubMed Central  PubMed  Google Scholar 

  • Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456

    CAS  PubMed  Google Scholar 

  • Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 72:5588–5599

    CAS  PubMed Central  PubMed  Google Scholar 

  • Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y (2014a) Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13:433–443

    CAS  PubMed Central  PubMed  Google Scholar 

  • Murai J, Josse R, Doroshow JH, Pommier Y (2014b) Schlafen 11 (SLFN11) is a critical determinant of cellular sensitivity to PARP inhibitors. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5–9; San Diego, CA Philadelphia (PA): AACR, Abstr #1718

    Google Scholar 

  • Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier YG (2014c) Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 349:408–416

    Google Scholar 

  • Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R (2012) Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumors. Clin Cancer Res 18:2625–2631

    CAS  PubMed  Google Scholar 

  • Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, Chen AP, Pommier Y, Doroshow JH, Yang SX (2011) Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle 10:4074–4082

    CAS  PubMed Central  PubMed  Google Scholar 

  • Norris RE, Adamson PC, Nguyen VT, Fox E (2014) Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr Blood Cancer 61:145–150

    CAS  PubMed  Google Scholar 

  • Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I et al (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11:129–135

    CAS  PubMed Central  PubMed  Google Scholar 

  • Onaga M, Ido A, Hasuike S, Uto H, Moriuchi A, Nagata K, Hori T, Hayash K, Tsubouchi H (2003) Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells. J Hepatol 39:779–785

    CAS  PubMed  Google Scholar 

  • Orentas RJ, Lee DW, Mackall C (2012a) Immunotherapy targets in pediatric cancer. Front Oncol 2:3

    PubMed Central  PubMed  Google Scholar 

  • Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J (2012b) Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front Oncol 2:194

    PubMed Central  PubMed  Google Scholar 

  • Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300–5309

    CAS  PubMed  Google Scholar 

  • Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, Gelderblom H, Hogendoorn PC, Egeler RM, Schilham MW, Lankester AC (2012) Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res 18:432–441

    CAS  PubMed  Google Scholar 

  • Palucka K, Banchereau J (2013) Dendritic-cell-based therapeutic cancer vaccines. Immunity 39:38–48

    CAS  PubMed Central  PubMed  Google Scholar 

  • Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R et al (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29:4541–4547

    CAS  PubMed Central  PubMed  Google Scholar 

  • Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP et al (2014) A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research through Collaboration study. Cancer 120:2448–2456

    Google Scholar 

  • Piha-Paul SA, Shin SJ, Vats T, Guha-Thakurta N, Aaron J, Rytting M, Kleinerman E, Kurzrock R (2014) Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. Anticancer Res 34:1939–1945

    CAS  PubMed  Google Scholar 

  • Plummer R (2010) Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res 16:4527–4531

    CAS  PubMed  Google Scholar 

  • Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG, MacDougall JR, Arrol S, Zhong H, Gerwien RW et al (2007) Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 60:423–435

    CAS  PubMed  Google Scholar 

  • Pollak M, Richard M (1990) Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 82:1349–1352

    CAS  PubMed  Google Scholar 

  • Pratt CB, Champion JE, Fleming ID, Rao B, Kumar AP, Evans WE, Green AA, George S (1990) Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies. Cancer 65:439–445

    CAS  PubMed  Google Scholar 

  • Prieur A, Tirode F, Cohen P, Delattre O (2004) EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24:7275–7283

    CAS  PubMed Central  PubMed  Google Scholar 

  • Rainusso N, Brawley VS, Ghazi A, Hicks MJ, Gottschalk S, Rosen JM, Ahmed N (2012) Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther 19:212–217

    CAS  PubMed  Google Scholar 

  • Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele KL, Vasko AJ et al (2007) Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst 99:1623–1633

    CAS  PubMed  Google Scholar 

  • Remsing LL, Bahadori HR, Carbone GM, McGuffie EM, Catapano CV, Rohr J (2003) Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target. Biochemistry 42:8313–8324

    CAS  PubMed  Google Scholar 

  • Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA et al (2013) Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer 60:791–798

    CAS  PubMed  Google Scholar 

  • Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA (2007) Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol 178:6557–6566

    CAS  PubMed  Google Scholar 

  • Rose AA, Siegel PM (2007) Osteoactivin/HGFIN: is it a tumor suppressor or mediator of metastasis in breast cancer? Breast Cancer Res 9:403

    PubMed Central  PubMed  Google Scholar 

  • Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M et al (2010) Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 16:2147–2156

    CAS  PubMed  Google Scholar 

  • Rosen G, Nirenberg A, Caparros B, Juergens H, Kosloff C, Mehta BM, Marcove RC, Huvos AG (1981) Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7). Natl Cancer Inst Monogr 56:213–220

    PubMed  Google Scholar 

  • Roth M, Linkowski M, Tarim J, Piperdi S, Sowers R, Geller D, Gill J, Gorlick R (2014) Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer 120:548–554

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sachdev D, Yee D (2006) Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia 11:27–39

    PubMed  Google Scholar 

  • Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1–12

    CAS  PubMed  Google Scholar 

  • Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D (2003) A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63:627–635

    CAS  PubMed  Google Scholar 

  • Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D (2006) Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 66:2391–2402

    CAS  PubMed  Google Scholar 

  • Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A et al (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14:882–892

    CAS  PubMed  Google Scholar 

  • Sangiolo D, Mesiano G, Gammaitoni L, Leuci V, Todorovic M, Giraudo L, Cammarata C, Dell’Aglio C, D’Ambrosio L, Pisacane A et al (2014) Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. Cancer Res 74:119–129

    CAS  PubMed  Google Scholar 

  • Schiewer MJ, Den R, Hoang DT, Augello MA, Lawrence YR, Dicker AP, Knudsen KE (2012) mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer 19:1–12

    CAS  PubMed Central  PubMed  Google Scholar 

  • Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH et al (2013) Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 14:371–382

    CAS  PubMed Central  PubMed  Google Scholar 

  • Schwarzbich MA, Gutknecht M, Salih J, Salih HR, Brossart P, Rittig SM, Grunebach F (2012) The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. Cancer Immunol Immunother 61:193–202

    CAS  PubMed  Google Scholar 

  • Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, Picci P, Manara MC, Baldini N (1996) Insulin-like growth factor I receptor-mediated circuit in Ewing’s sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 56:4570–4574

    CAS  PubMed  Google Scholar 

  • Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Serra M, Manara MC, Picci P, Baldini N (1998) Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing’s sarcoma in athymic mice. Cancer Res 58:4127–4131

    CAS  PubMed  Google Scholar 

  • Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M et al (2005) Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65:3868–3876

    CAS  PubMed  Google Scholar 

  • Shen C, Oswald D, Phelps D, Cam H, Pelloski CE, Pang Q, Houghton PJ (2013) Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks. Cancer Res 73:3393–3401

    CAS  PubMed Central  PubMed  Google Scholar 

  • Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (2010a) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331–1337

    CAS  PubMed Central  PubMed  Google Scholar 

  • Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, Smith FO, Reaman GH (2010b) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28:2625–2634

    PubMed Central  PubMed  Google Scholar 

  • Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST et al (2015) Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 62:91–98

    CAS  PubMed  Google Scholar 

  • Soldatenkov VA, Albor A, Patel BK, Dreszer R, Dritschilo A, Notario V (1999) Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor. Oncogene 18:3954–3962

    CAS  PubMed  Google Scholar 

  • Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, Wierzbicki R, Malcolm AJ, Kirkpatrick A, Uscinska BM et al (1997) Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350:911–917

    CAS  PubMed  Google Scholar 

  • Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, Berkenblit A, Krygowski M, Ananthakrishnan R, Boni JP, Gilbertson RJ (2011) Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 29:2933–2940

    CAS  Google Scholar 

  • Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein H, Zeng J, Nascimento PR, Sequeira VB, Butler TL et al (2013) A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Res 73:5169–5182

    CAS  PubMed  Google Scholar 

  • Suminoe A, Matsuzaki A, Hattori H, Koga Y, Hara T (2009) Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediatr Transplant 13:746–753

    CAS  PubMed  Google Scholar 

  • Sutow WW (1968) Vincristine (NSC-67574) therapy for malignant solid tumors in children (except Wilms’ tumor). Cancer Chemother Rep Part 1 1(52):485–487

    Google Scholar 

  • Sutow WW, Vietti TJ, Fernbach DJ, Lane DM, Donaldson MH, Lonsdale D (1971) Evaluation of chemotherapy in children with metastatic Ewing’s sarcoma and osteogenic sarcoma. Cancer Chemother Rep Part 1 55:67–78

    CAS  Google Scholar 

  • Taur JS, Desjardins CS, Schuck EL, Wong YN (2011) Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells. Xenobiotica 41:320–326

    CAS  PubMed  Google Scholar 

  • Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA et al (2013) Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121:5154–5157

    CAS  PubMed Central  PubMed  Google Scholar 

  • Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Carrera-Haro MA, Ferreira MF, Shafique U, Powell JD et al (2013) A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer J Int Cancer 133:997–1005

    CAS  Google Scholar 

  • Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, Ames E, Bruhn KW, Craft N, Wiltrout RH et al (2012) Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood 119:3073–3083

    CAS  PubMed Central  PubMed  Google Scholar 

  • Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS et al (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol Off J Am Soc Clin Oncol 27:5800–5807

    CAS  Google Scholar 

  • Tomihari M, Hwang SH, Chung JS, Cruz PD Jr, Ariizumi K (2009) Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion. Exp Dermatol 18:586–595

    CAS  PubMed Central  PubMed  Google Scholar 

  • Toretsky JA, Gorlick R (2010) IGF-1R targeted treatment of sarcoma. Lancet Oncol 11:105–106

    PubMed  Google Scholar 

  • Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP, Rice AM, Lee SB, Uren A (2006) Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res 66:5574–5581

    CAS  PubMed  Google Scholar 

  • Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH et al (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013–1021

    CAS  PubMed  Google Scholar 

  • Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ, Littlefield BA (2011) Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 71:496–505

    CAS  PubMed  Google Scholar 

  • Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL et al (2006) CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 12:1373–1382

    CAS  PubMed  Google Scholar 

  • Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235–244

    CAS  PubMed  Google Scholar 

  • Wan X, Mendoza A, Khanna C, Helman LJ (2005) Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65:2406–2411

    CAS  PubMed  Google Scholar 

  • Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26:1932–1940

    CAS  PubMed  Google Scholar 

  • Wang Y, Hailey J, Williams D, Wang Y, Lipari P, Malkowski M, Wang X, Xie L, Li G, Saha D et al (2005) Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 4:1214–1221

    CAS  PubMed  Google Scholar 

  • Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM (2014) Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 61:452–456

    CAS  PubMed  Google Scholar 

  • Wittman MD, Balasubramanian B, Stoffan K, Velaparthi U, Liu P, Krishnanathan S, Carboni J, Li A, Greer A, Attar R et al (2007) Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase. Bioorg Med Chem Lett 17:974–977

    CAS  PubMed  Google Scholar 

  • Wittrant Y, Lamoureux F, Mori K, Riet A, Kamijo A, Heymann D, Redini F (2006) RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 28:261–269

    CAS  PubMed  Google Scholar 

  • Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF et al (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347–5356

    CAS  PubMed  Google Scholar 

  • Workenhe ST, Mossman KL (2014) Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther 22:251–256

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471–484

    CAS  PubMed  Google Scholar 

  • Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE et al (2014) Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123:3750–3759

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yee D (2012) Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 104:975–981

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yi H, Fujimura Y, Ouchida M, Prasad DD, Rao VN, Reddy ES (1997) Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene 14:1259–1268

    CAS  PubMed  Google Scholar 

  • Yu Z, Ma B, Zhou Y, Zhang M, Qiu X, Fan Q (2005) Activation of antitumor cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous osteosarcoma. Exp Oncol 27:273–278

    CAS  PubMed  Google Scholar 

  • Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324–1334

    CAS  PubMed Central  PubMed  Google Scholar 

  • Zucman J, Delattre O, Desmaze C, Plougastel B, Joubert I, Melot T, Peter M, De Jong P, Rouleau G, Aurias A et al (1992) Cloning and characterization of the Ewing’s sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer 5:271–277

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology/BMT, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH, 43205, USA

    Timothy P. Cripe MD, PhD & Kellie B. Haworth MD

  2. Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH, 43205, USA

    Peter J. Houghton PhD

Authors
  1. Timothy P. Cripe MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kellie B. Haworth MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter J. Houghton PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter J. Houghton PhD .

Editor information

Editors and Affiliations

  1. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children’s Hospital, Columbus, Ohio, USA

    Timothy P. Cripe

  2. Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children’s Hospital, Columbus, Ohio, USA

    Nicholas D. Yeager

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Cripe, T.P., Haworth, K.B., Houghton, P.J. (2015). Novel Therapies on the Horizon. In: Cripe, T., Yeager, N. (eds) Malignant Pediatric Bone Tumors - Treatment & Management. Pediatric Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18099-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18099-1_15

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18098-4

  • Online ISBN: 978-3-319-18099-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation